Puma Biotechnology (PBYI) Short term Debt (2019 - 2026)
Puma Biotechnology's (PBYI) quarterly Short term Debt came in at $11.3 million in Q1 2026, down 75.11% YoY from $45.3 million in Q1 2025, and down 49.9% on a QoQ basis from $22.5 million in Q4 2025.
Puma Biotechnology (PBYI) Short term Debt (2019 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 7 years of Short term Debt data on file, last reported at $11.3 million in Q1 2026.
- Quarterly Short term Debt fell 75.11% year-over-year to $11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (down 75.11% YoY) and the FY2025 annual result came in at $22.5 million, down 50.31% from the prior year.
- Short term Debt retreated to $11.3 million in Q1 2026, from $22.5 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $45.3 million in Q1 2024 to a low of $11.3 million in Q1 2026.
- A 4-year average of $33.0 million and a median of $34.0 million in 2023 frame the typical range for Short term Debt.
- Annual changes were most pronounced in 2024 — Short term Debt jumped 300.01% — and 2026, when it tumbled 75.11%.
- Tracing PBYI's Short term Debt over 4 years: stood at $34.0 million in 2023, then surged by 33.33% to $45.3 million in 2024, then plunged by 50.31% to $22.5 million in 2025, then tumbled by 49.9% to $11.3 million in 2026.
- The last three Short term Debt figures came in at $11.3 million (Q1 2026), $22.5 million (Q4 2025), and $33.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.28 Mn |
| Dec 31, 2025 | 22.52 Mn |
| Sep 30, 2025 | 33.72 Mn |
| Jun 30, 2025 | 34.00 Mn |
| Mar 31, 2025 | 45.33 Mn |
| Dec 31, 2024 | 45.33 Mn |
| Sep 30, 2024 | 45.33 Mn |
| Jun 30, 2024 | 45.33 Mn |
| Mar 31, 2024 | 45.33 Mn |
| Dec 31, 2023 | 34.00 Mn |
| Sep 30, 2023 | 22.66 Mn |
| Jun 30, 2023 | 11.33 Mn |
| Jun 30, 2021 | 31.43 Mn |
| Mar 31, 2021 | 22.86 Mn |
| Dec 31, 2020 | 14.29 Mn |
| Sep 30, 2020 | 5.71 Mn |
| Jun 30, 2020 | 14.29 Mn |
| Mar 31, 2020 | 14.29 Mn |
| Dec 31, 2019 | 34.29 Mn |